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); however, it significantly 145 decreased the number of fibroblasts that invaded the gel ( Supplementary Fig. S1F ).
146
Therefore, it appears that paxillin suppression has different effects on cell migration 147 in vivo depending on the cell type.
148

Paxillin controls retinal angiogenesis in vivo 149
We then examined whether paxillin is also important for control of normal and migration in response to VEGF (Favier et al., 2006; Takashima et al., 2002) .
169
Therefore, we examined whether paxillin might control endothelial cell migration by 170 altering NRP2 expression. siRNA-mediated knockdown of paxillin resulted in a 50% 171 decrease in NRP2 expression at both protein and mRNA levels in cultured HUVE 172 cells ( Fig. 4A-C) . To determine whether these effects are specific for paxillin, we increased by 1.5-fold (Fig. 4D) , and invasion into Matrigel doubled (Fig. 4E, F, 179 second panel), much as it did when paxillin was knocked down in these cells (Fig. 180 1C-E). Importantly, over-expression of NRP2, which increases NRP2 mRNA and 181 protein levels in CE cells ( Supplementary Fig. S2D-F) , was able to prevent the pax 182 k/d-induced increase of HUVE cell migration and invasion ( Fig. 4D-F) . Thus, NRP2 183 appears to mediate the effects of paxillin on endothelial cell motility and invasion in 184 vitro. 185 We previously showed that overexpression of a paxillin N-terminal (paxN) 186 truncation mutant in paxillin knockout mouse embryonic fibroblasts resulted in a 187 significant increase in their invasive behavior, whereas expression of a C-terminal 188 (paxC) truncation mutant had the opposite effect (Sero et al., 2011) . To further 189 analyze the molecular mechanism through which paxillin controls endothelial cell produce any significant change in migratory behavior ( Supplementary Fig. S2H ).
196
Importantly, this migration-stimulating effect of overexpressing paxN in paxillin 197 knockdown HUVE cells was accompanied by a decrease in NRP2 protein levels 198 whereas paxC overexpression had no effect of NRP2 protein expression 199 ( Supplementary Fig. S2G ). Therefore, the N-terminal portion of paxillin appears to mediate its ability to promote migration in endothelial cells by suppressing NRP2 201 expression.
202
To determine the physiological relevance of these effects, we measured the 203 expression of NRP2 in CE cells that infiltrated Matrigel plug implants in the in vivo 204 Matrigel capillary invasion assay when we knocked down paxillin expression. NRP2 205 expression decreased by 40% in CE cells, as measured by image analysis, when 206 paxillin siRNA was injected subcutaneously (Fig. 5A, B) , and a similar decrease in 207 NRP2 mRNA level was measured by analyzing total mRNA in gel implants using 208 qRT-PCR (Fig. 5C ). We then injected NRP2-specific siRNA subcutaneously, and 209 found that it produced ~60% knockdown of NRP2 protein and mRNA levels Supplementary Fig. S3D ); however, it specifically produced 213 an increase in endothelial cell migration resulting in significantly enhanced capillary 214 ingrowth into the gel (Fig. 5D, E ). This resulted in the appearance of a higher number 215 of CE cells at increasing distances into the gel relative to control gels (Fig. 5F ),
216
hence mimicking the results we observed by knocking down paxillin (Fig. 2F) . In Fig. S3F-H ).
230
Thus, paxillin appears to exert its angiogenesis-modulating effects by selectively 231 altering NRP2 expression.
Paxillin mediates tumor-induced angiogenesis
233
Formation of well-organized microvessels is necessary for normal organ 234 development and deregulation of this process contributes to cancer progression, as 235 well as development of tumor resistance to cancer therapies (Carmeliet and Jain, 236 2011; Chung and Ferrara, 2011) . We therefore set out to examine whether paxillin is 237 also involved in control of tumor-induced angiogenesis. To do this, we implanted a
238
Matrigel plug subcutaneously within one chamber of a 2-chamber PDMS device that 239 contained Lewis lung carcinoma (LLC) cells in the second chamber, separated from 240 the Matrigel by a porous filter membrane ( Supplementary Fig. S4A (Fig. 6A, B ) and qRT-PCR of extracted gels (Fig. 6C) , respectively. The in CE cells by 40% (Fig. 6A, B (Fig. 6A-C) .
269
Moreover, NRP2 expression decreased by at least 50% when the cultured HUVE 270 cells were stimulated with LLC factors that also decrease paxillin expression ( Fig.   271 7A-C), whereas over-expression of paxillin restored normal NRP2 levels ( Fig. 7A-C) .
272
Thus, again, NRP2 appears to be downstream of paxillin in this signaling pathway.
273
When we examined the effects of LLC-derived factors on HUVE cell migration 274 and invasion in vitro, the tumor factors increased the number of migrating cells that 275 invaded into the Matrigel plugs by 1.5-fold and 2-fold, respectively ( Fig. 7D-F) .
276
Furthermore, when we over-expressed paxillin in LLC factor-treated cells, cell 277 migration and invasion were restored to control levels ( Fig. 7D-F) . Similar 278 normalization of CE cell migration and ECM invasion was also obtained by over-279 expressing NRP2 (Fig. 7D-F) .
280
VEGF decreases paxillin expression and NRP2 expression
281
As VEGF is a major angiogenic chemoattractant produced by LLC cells 282 (Satchi-Fainaro et al., 2005) and NRP2 is a VEGF receptor, we explored whether 283 VEGF could be responsible for the effects of tumor-derived factors on paxillin and 284 NRP2 expression that we observed. VEGF alone decreased paxillin expression by 285 about 80% when measured by qRT-PCR (Fig. 7G ), in addition to suppressing 286 expression of NRP2 mRNA (Fig. 7G) , much as we observed in our studies with LLC-287 derived factors. Moreover, paxillin over-expression in combination with VEGF was 288 able to reverse the suppression of NRP2 mRNA levels (Fig. 7G) . Importantly, VEGF- showed that paxillin is decreased in lung, breast and colorectal tumors, among 391 others (Deakin et al., 2012; Salgia et al., 1999; Yang et al., 2010) . This seems to be controversial as paxillin expression also has been reported to be elevated in lung, 393 prostate, breast, cervical and other tumors (Deakin et al., 2012; Jagadeeswaran et 394 al., 2008; Mackinnon et al., 2011; Salgia et al., 1999; Sen et al., 2012 Clifton, NJ, USA) ( Supplementary Fig. S4A ). 10 µg of siRNA paxillin, siRNA NRP2 or 496 scramble control siRNA was injected locally at day 3 after implantation. Fluorescein-497 conA (Vector Laboratories, Burlingame, CA, USA) was injected into the retro-orbital 498 vein prior to harvesting at day 7. Implants were fixed, frozen, sectioned and stained 499 with hematoxylin and eosin (H&E), anti-CD31, paxillin, NRP2, VEGFR2 and DAPI 500 antibodies. H&E stained images were taken on a Nikon Eclipse E600 microscope, 
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